Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study.

Graeff C, Chevalier Y, Charlebois M, Varga P, Pahr D, Nickelsen TN, Morlock MM, Glüer CC, Zysset PK.

J Bone Miner Res. 2009 Oct;24(10):1672-80. doi: 10.1359/jbmr.090416.

2.

Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study.

Graeff C, Timm W, Nickelsen TN, Farrerons J, Marín F, Barker C, Glüer CC; EUROFORS High Resolution Computed Tomography Substudy Group.

J Bone Miner Res. 2007 Sep;22(9):1426-33.

3.

Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.

Chevalier Y, Quek E, Borah B, Gross G, Stewart J, Lang T, Zysset P.

Bone. 2010 Jan;46(1):41-8. doi: 10.1016/j.bone.2009.09.032. Epub 2009 Oct 1.

PMID:
19800436
4.

Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis.

Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA.

J Bone Miner Res. 2007 Jan;22(1):149-57.

5.

Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).

Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Brixen K, Gomes JM, Obermayer-Pietsch B, Avramidis A, Sigurdsson G, Glüer CC.

J Bone Miner Res. 2009 Apr;24(4):726-36. doi: 10.1359/jbmr.081215.

6.
7.

Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.

Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH.

J Bone Miner Res. 2006 Nov;21(11):1785-90.

8.

Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis.

Chen P, Miller PD, Recker R, Resch H, Rana A, Pavo I, Sipos AA.

J Bone Miner Res. 2007 Aug;22(8):1173-80.

9.

Structural determinants of vertebral fracture risk.

Melton LJ 3rd, Riggs BL, Keaveny TM, Achenbach SJ, Hoffmann PF, Camp JJ, Rouleau PA, Bouxsein ML, Amin S, Atkinson EJ, Robb RA, Khosla S.

J Bone Miner Res. 2007 Dec;22(12):1885-92.

10.

Prediction of vertebral strength under loading conditions occurring in activities of daily living using a computed tomography-based nonlinear finite element method.

Matsumoto T, Ohnishi I, Bessho M, Imai K, Ohashi S, Nakamura K.

Spine (Phila Pa 1976). 2009 Jun 15;34(14):1464-9. doi: 10.1097/BRS.0b013e3181a55636.

PMID:
19525837
11.

Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment.

Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T; EUROFORS Investigators.

J Bone Miner Res. 2008 Oct;23(10):1591-600. doi: 10.1359/jbmr.080506.

12.

Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.

Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.

Bone. 2006 Dec;39(6):1268-75. Epub 2006 Aug 1.

PMID:
16884968
13.

Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.

Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.

J Am Geriatr Soc. 2006 May;54(5):782-9.

PMID:
16696744
14.

Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study.

Miyauchi A, Matsumoto T, Shigeta H, Tsujimoto M, Thiebaud D, Nakamura T.

J Bone Miner Metab. 2008;26(6):624-34. doi: 10.1007/s00774-008-0871-3. Epub 2008 Nov 1.

PMID:
18979163
15.

Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method.

Imai K, Ohnishi I, Matsumoto T, Yamamoto S, Nakamura K.

Osteoporos Int. 2009 May;20(5):801-10. doi: 10.1007/s00198-008-0750-8. Epub 2008 Sep 18.

PMID:
18800178
16.

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.

Ettinger B, San Martin J, Crans G, Pavo I.

J Bone Miner Res. 2004 May;19(5):745-51. Epub 2004 Jan 19.

17.

Femoral strength in osteoporotic women treated with teriparatide or alendronate.

Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K.

Bone. 2012 Jan;50(1):165-70. doi: 10.1016/j.bone.2011.10.002. Epub 2011 Oct 17.

PMID:
22015818
18.

Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial.

Glüer CC, Marin F, Ringe JD, Hawkins F, Möricke R, Papaioannu N, Farahmand P, Minisola S, Martínez G, Nolla JM, Niedhart C, Guañabens N, Nuti R, Martín-Mola E, Thomasius F, Kapetanos G, Peña J, Graeff C, Petto H, Sanz B, Reisinger A, Zysset PK.

J Bone Miner Res. 2013 Jun;28(6):1355-68. doi: 10.1002/jbmr.1870.

19.

A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study.

Kung AW, Pasion EG, Sofiyan M, Lau EM, Tay BK, Lam KS, Wilawan K, Ongphiphadhanakul B, Thiebaud D.

Curr Med Res Opin. 2006 May;22(5):929-37.

PMID:
16709314
20.

A rat osteoporotic spine model for the evaluation of bioresorbable bone cements.

Wang ML, Massie J, Perry A, Garfin SR, Kim CW.

Spine J. 2007 Jul-Aug;7(4):466-74. Epub 2007 Apr 6.

PMID:
17630145
Items per page

Supplemental Content

Write to the Help Desk